Table 6 Heterogeneity and subgroup analyses of each included study
From: Intra-articular platelet-rich plasma injection for knee osteoarthritis: a summary of meta-analyses
| Â | Kanchanatawan et al. | Dai et al. | Xu et al. | Shen et al. | |||
|---|---|---|---|---|---|---|---|
PRP v HA | PRP v placebo | PRP v HA | PRP v placebo | PRP v HA | PRP v placebo | PRP v Control | |
Statistical heterogeneity analysis | + | + | + | + | |||
Subgroup or sensitivity analysis | |||||||
 Primary study quality | + | + | + | + | |||
 Age | – | – | – | – | |||
 Gender | – | – | – | – | |||
 OA grade | – | – | – | – | |||
 WOMAC total score | + (≤ 1 year) | + (≤ 1 year) | + (6, 12 months) | +(6, 12 months) | + (3, 6, 12 months) | +(6 months) | +(3, 6, 12 months) |
 WOMAC pain score | + (≤ 1 year) | + (≤ 1 year) | + (6, 12 months) | +(6, 12 months) | – | – | +(3, 6, 12 months) |
 WOMAC functional score | + (≤ 1 year) | + (≤ 1 year) | + (6, 12 months) | +(6, 12 months) | – | – | +(3, 6, 12 months) |
 Lequesne score | + (≤ 1 year) | – | + (6, 12 months) | – | + (6 months) | – | – |
 IKDC score | + (≤ 1 year) | – | + (6, 12 months) | – | + (6 months) | +(6 months) | – |
 VAS score | + (≤ 1 year) | – | – | – | + (6 months) | – | – |
 Adverse events | + | + | + | + | – | – | + |
 No. of PRP injection (1 or ≥ 2); PRP spinning approach (single or double); mean platelet concentration (> or < 5*baseline); LP or LR PRP; with an activator or not, risk of bias | – | + | – | – | |||